AnterogenCoLtd (Korea) Performance
| 065660 Stock | KRW 15,570 190.00 1.24% |
AnterogenCoLtd has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -0.0337, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning AnterogenCoLtd are expected to decrease at a much lower rate. During the bear market, AnterogenCoLtd is likely to outperform the market. AnterogenCoLtd right now shows a risk of 2.19%. Please confirm AnterogenCoLtd standard deviation, total risk alpha, treynor ratio, as well as the relationship between the jensen alpha and sortino ratio , to decide if AnterogenCoLtd will be following its price patterns.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in AnterogenCoLtd are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite somewhat strong basic indicators, AnterogenCoLtd is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Total Cashflows From Investing Activities | -14.4 B |
AnterogenCoLtd |
AnterogenCoLtd Relative Risk vs. Return Landscape
If you would invest 1,513,000 in AnterogenCoLtd on August 31, 2024 and sell it today you would earn a total of 44,000 from holding AnterogenCoLtd or generate 2.91% return on investment over 90 days. AnterogenCoLtd is generating 0.0728% of daily returns and assumes 2.1867% volatility on return distribution over the 90 days horizon. Simply put, 19% of stocks are less volatile than AnterogenCoLtd, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
AnterogenCoLtd Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for AnterogenCoLtd's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as AnterogenCoLtd, and traders can use it to determine the average amount a AnterogenCoLtd's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0333
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | 065660 | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.19 actual daily | 19 81% of assets are more volatile |
Expected Return
| 0.07 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average AnterogenCoLtd is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of AnterogenCoLtd by adding it to a well-diversified portfolio.
AnterogenCoLtd Fundamentals Growth
AnterogenCoLtd Stock prices reflect investors' perceptions of the future prospects and financial health of AnterogenCoLtd, and AnterogenCoLtd fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AnterogenCoLtd Stock performance.
| Return On Equity | -5.92 | |||
| Return On Asset | -0.0231 | |||
| Profit Margin | (1.32) % | |||
| Operating Margin | (0.77) % | |||
| Current Valuation | 836.51 B | |||
| Shares Outstanding | 7.95 M | |||
| Price To Sales | 103.53 X | |||
| Revenue | 8.12 B | |||
| EBITDA | (2.96 B) | |||
| Cash And Equivalents | 6.97 B | |||
| Debt To Equity | 43.70 % | |||
| Cash Flow From Operations | (3.05 B) | |||
| Total Asset | 136.7 B | |||
About AnterogenCoLtd Performance
By analyzing AnterogenCoLtd's fundamental ratios, stakeholders can gain valuable insights into AnterogenCoLtd's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if AnterogenCoLtd has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if AnterogenCoLtd has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
,Ltd., a bio-venture company, engages in the research, development, and commercialization of stem cell therapy products using adipose-derived stem cells in South Korea and internationally. ,Ltd. was founded in 2000 and is headquartered in Seoul, South Korea. ANTEROGEN is traded on Korean Securities Dealers Automated Quotations in South Korea.Things to note about AnterogenCoLtd performance evaluation
Checking the ongoing alerts about AnterogenCoLtd for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AnterogenCoLtd help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the revenue of 8.12 B. Net Loss for the year was (553.98 M) with profit before overhead, payroll, taxes, and interest of 1.72 B. | |
| AnterogenCoLtd has accumulated about 6.97 B in cash with (3.05 B) of positive cash flow from operations. | |
| Roughly 21.0% of the company shares are owned by insiders or employees |
- Analyzing AnterogenCoLtd's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AnterogenCoLtd's stock is overvalued or undervalued compared to its peers.
- Examining AnterogenCoLtd's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AnterogenCoLtd's management team can have a significant impact on its success or failure. Reviewing the track record and experience of AnterogenCoLtd's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AnterogenCoLtd's stock. These opinions can provide insight into AnterogenCoLtd's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for AnterogenCoLtd Stock analysis
When running AnterogenCoLtd's price analysis, check to measure AnterogenCoLtd's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AnterogenCoLtd is operating at the current time. Most of AnterogenCoLtd's value examination focuses on studying past and present price action to predict the probability of AnterogenCoLtd's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AnterogenCoLtd's price. Additionally, you may evaluate how the addition of AnterogenCoLtd to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |